Substantia Nigra (SN) Hyperechogenicity as seen in Transcranial Sonography (TCS) is a reliable disease progression marker from Stage I to Stage II in Early Onset Parkinson’s Disease (EOPD)
Objective: To test the hypothesis that SN hyperechogenicity seen in transcranial sonography (TCS) can be used as a reliable disease progression marker from stage I…Evaluation of neuroprotection by human ENGRAILED-1 in a chronic AAV-hα-synuclein-A53T (AAV-A53T) rat model of Parkinson Disease
Objective: Investigate the long-term neuroprotective effect of a single bilateral injection of human ENGRAILED1 (hEN1) in a rat α-synuclein model of Parkinson Disease (PD). Background:…Safety of Bone marrow-derived Allogeneic Mesenchymal Stem Cells in Parkinson’s disease Patients
Objective: Prove safety and tolerability of allogeneic mesenchymal stem cells (MSC) purified from bone marrow derived from a healthy adult and delivered intravenously in escalated…Pre-diagnosis physical activity habits are associated with age of diagnosis and postural instability in Parkinson’s disease
Objective: To determine if pre-diagnosis exercise and brain-derived neurotrophic factor (BDNF) genotype are predictive of age at diagnosis and severity of balance impairment. Background: Studies…Metabolomic Analysis of Fecal Matter from Parkinsonian Mice
Objective: Assess the metabolic changes in fecal matter in mice treated with an immunomodulatory therapy. Background: The cause of neuronal death in Parkinson’s disease (PD)…K0706, A Potent Orally Bioavailable Brain-Penetrating Selective Inhibitor of cABL Protein Tyrosine Kinase, Exhibits Neuroprotective Activity in Preclinical Models of Parkinson’s Disease
Objective: Preclinical assessment of K0706, a potent c-Abl inhibitor, as a neuroprotective disease modifying agent for the treatment of Parkinson’s disease (PD) related neurodegeneration using…Osteopathic Manipulative Medicine to Improve Balance and Quality of Life in Parkinson Disease
Objective: To examine the effects of Osteopathic Manipulative Medicine (OMM) using a pre-defined protocol for 6 weeks and compare that to a 6-week counseling protocol…Advanced Stage of Parkinson’s Disease: From Identification to Characterization and Disease Burden Assessment Using a Nationwide Database
Objective: To identify and describe PD patients who were prescribed intensified therapy and compare their burden of disease with mild-moderate PD patients. Background: Real-world data…Clinical and DAT Imaging Characteristics of Participants with Scans without Evidence of Dopaminergic Deficit (SWEDDs): PPMI Cohort 2 year follow-up
Objective: To examine the clinical and biological characteristics of participants with scans without evidence of dopaminergic deficit (SWEDD) during a two-year follow-up. Background: Study participants…Translating Preclinical Data to a Human Equivalent Dose for AMT-130 AAV Gene Therapy for Early Manifest Huntington’s Disease
Objective: To extrapolate the human equivalent dose (HED) for a Phase I/II clinical trial in adults to explore the safety, tolerability, and efficacy of striatally-administered…
- « Previous Page
- 1
- …
- 11
- 12
- 13
- 14
- 15
- …
- 19
- Next Page »